Drug Profile
Nilotinib - Inhibikase Therapeutics
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Inhibikase Therapeutics
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 22 Oct 2020 Discontinued - Phase-II for Parkinson's disease in USA (PO) (Inhibikase Therapeutics' pipeline, October 2020)
- 21 Apr 2017 Chemical structure information added
- 24 Mar 2017 Phase-II clinical trials in Parkinson's disease in USA (PO) (Inhibikase pipeline, March 2017)